Pharmacogenetic Impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate

Lina Palacio, Diana Falla, Ignacio Tobon, Fernando Mejia, John E Lewis, Ariel F. Martinez, Mauricio Arcos-Burgos, Mauricio Camargo

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Warfarin is the most prescribed oral anticoagulant worldwide. Because of the complexity of warfarin therapy, we attempted to dissect genetic from bioenvironmental factors influencing warfarin dose responses in individuals of a genetic isolate of Hispanic ancestry. A total of 191 patients with standard values of international normalized ratio were recruited. Three groups with a significantly different warfarin dose response were identified, that is, sensitive (2.28 ± 0.50 mg/d), intermediate (4.2 ± 0.76 mg/d), and resistant (7.40 ± 1.54 mg/d; Tukey test, P <001). Age had a significant inverse correlation with warfarin dose (P <001; effective dose diminished 0.56 mg/d/decade). Required doses were higher for individuals with CYP2C9 variants containing the allele *1 compared to those individuals with variants composed of other alleles (P =.006). Similarly, individuals with VKORC1-1639GG and VKORC1-1639GA genotypes also required higher doses compared to the AA genotype (P <001). Evaluation of potential gene-gene interactions between CYP2C9 and VKORC1 polymorphisms showed significant differences in dosing for CYP2C9 genotypes within the VKORC1-1639G/A subgroup (P =.013). A stepwise multivariate linear regression analysis showed that 38.2% of the warfarin dose response variance was accounted for by a model involving age (20.9%), VKORC1-1639G/A (11.3%), and CYP2C9*1, *2, and *3 variants (7.1%). These results corroborate previous findings on warfarin pharmacogenetics and define a contrastable gene-bioenvironment interaction model suited to be used in Hispanic populations.

Original languageEnglish
Pages (from-to)83-90
Number of pages8
JournalClinical and Applied Thrombosis/Hemostasis
Volume16
Issue number1
DOIs
StatePublished - Feb 1 2010

Fingerprint

Pharmacogenetics
Warfarin
Hispanic Americans
Population
Genotype
Alleles
Genes
International Normalized Ratio
Cytochrome P-450 CYP2C9
Anticoagulants
Linear Models
Regression Analysis

Keywords

  • Colombia
  • CYP2C9
  • Genetic isolate
  • Pharmacogenetics
  • VKORC1
  • Warfarin

ASJC Scopus subject areas

  • Hematology

Cite this

Pharmacogenetic Impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate. / Palacio, Lina; Falla, Diana; Tobon, Ignacio; Mejia, Fernando; Lewis, John E; Martinez, Ariel F.; Arcos-Burgos, Mauricio; Camargo, Mauricio.

In: Clinical and Applied Thrombosis/Hemostasis, Vol. 16, No. 1, 01.02.2010, p. 83-90.

Research output: Contribution to journalArticle

Palacio, Lina ; Falla, Diana ; Tobon, Ignacio ; Mejia, Fernando ; Lewis, John E ; Martinez, Ariel F. ; Arcos-Burgos, Mauricio ; Camargo, Mauricio. / Pharmacogenetic Impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate. In: Clinical and Applied Thrombosis/Hemostasis. 2010 ; Vol. 16, No. 1. pp. 83-90.
@article{30666d66886a45c394f39685a412503f,
title = "Pharmacogenetic Impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate",
abstract = "Warfarin is the most prescribed oral anticoagulant worldwide. Because of the complexity of warfarin therapy, we attempted to dissect genetic from bioenvironmental factors influencing warfarin dose responses in individuals of a genetic isolate of Hispanic ancestry. A total of 191 patients with standard values of international normalized ratio were recruited. Three groups with a significantly different warfarin dose response were identified, that is, sensitive (2.28 ± 0.50 mg/d), intermediate (4.2 ± 0.76 mg/d), and resistant (7.40 ± 1.54 mg/d; Tukey test, P <001). Age had a significant inverse correlation with warfarin dose (P <001; effective dose diminished 0.56 mg/d/decade). Required doses were higher for individuals with CYP2C9 variants containing the allele *1 compared to those individuals with variants composed of other alleles (P =.006). Similarly, individuals with VKORC1-1639GG and VKORC1-1639GA genotypes also required higher doses compared to the AA genotype (P <001). Evaluation of potential gene-gene interactions between CYP2C9 and VKORC1 polymorphisms showed significant differences in dosing for CYP2C9 genotypes within the VKORC1-1639G/A subgroup (P =.013). A stepwise multivariate linear regression analysis showed that 38.2{\%} of the warfarin dose response variance was accounted for by a model involving age (20.9{\%}), VKORC1-1639G/A (11.3{\%}), and CYP2C9*1, *2, and *3 variants (7.1{\%}). These results corroborate previous findings on warfarin pharmacogenetics and define a contrastable gene-bioenvironment interaction model suited to be used in Hispanic populations.",
keywords = "Colombia, CYP2C9, Genetic isolate, Pharmacogenetics, VKORC1, Warfarin",
author = "Lina Palacio and Diana Falla and Ignacio Tobon and Fernando Mejia and Lewis, {John E} and Martinez, {Ariel F.} and Mauricio Arcos-Burgos and Mauricio Camargo",
year = "2010",
month = "2",
day = "1",
doi = "10.1177/1076029608330472",
language = "English",
volume = "16",
pages = "83--90",
journal = "Clinical and Applied Thrombosis/Hemostasis",
issn = "1076-0296",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Pharmacogenetic Impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate

AU - Palacio, Lina

AU - Falla, Diana

AU - Tobon, Ignacio

AU - Mejia, Fernando

AU - Lewis, John E

AU - Martinez, Ariel F.

AU - Arcos-Burgos, Mauricio

AU - Camargo, Mauricio

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Warfarin is the most prescribed oral anticoagulant worldwide. Because of the complexity of warfarin therapy, we attempted to dissect genetic from bioenvironmental factors influencing warfarin dose responses in individuals of a genetic isolate of Hispanic ancestry. A total of 191 patients with standard values of international normalized ratio were recruited. Three groups with a significantly different warfarin dose response were identified, that is, sensitive (2.28 ± 0.50 mg/d), intermediate (4.2 ± 0.76 mg/d), and resistant (7.40 ± 1.54 mg/d; Tukey test, P <001). Age had a significant inverse correlation with warfarin dose (P <001; effective dose diminished 0.56 mg/d/decade). Required doses were higher for individuals with CYP2C9 variants containing the allele *1 compared to those individuals with variants composed of other alleles (P =.006). Similarly, individuals with VKORC1-1639GG and VKORC1-1639GA genotypes also required higher doses compared to the AA genotype (P <001). Evaluation of potential gene-gene interactions between CYP2C9 and VKORC1 polymorphisms showed significant differences in dosing for CYP2C9 genotypes within the VKORC1-1639G/A subgroup (P =.013). A stepwise multivariate linear regression analysis showed that 38.2% of the warfarin dose response variance was accounted for by a model involving age (20.9%), VKORC1-1639G/A (11.3%), and CYP2C9*1, *2, and *3 variants (7.1%). These results corroborate previous findings on warfarin pharmacogenetics and define a contrastable gene-bioenvironment interaction model suited to be used in Hispanic populations.

AB - Warfarin is the most prescribed oral anticoagulant worldwide. Because of the complexity of warfarin therapy, we attempted to dissect genetic from bioenvironmental factors influencing warfarin dose responses in individuals of a genetic isolate of Hispanic ancestry. A total of 191 patients with standard values of international normalized ratio were recruited. Three groups with a significantly different warfarin dose response were identified, that is, sensitive (2.28 ± 0.50 mg/d), intermediate (4.2 ± 0.76 mg/d), and resistant (7.40 ± 1.54 mg/d; Tukey test, P <001). Age had a significant inverse correlation with warfarin dose (P <001; effective dose diminished 0.56 mg/d/decade). Required doses were higher for individuals with CYP2C9 variants containing the allele *1 compared to those individuals with variants composed of other alleles (P =.006). Similarly, individuals with VKORC1-1639GG and VKORC1-1639GA genotypes also required higher doses compared to the AA genotype (P <001). Evaluation of potential gene-gene interactions between CYP2C9 and VKORC1 polymorphisms showed significant differences in dosing for CYP2C9 genotypes within the VKORC1-1639G/A subgroup (P =.013). A stepwise multivariate linear regression analysis showed that 38.2% of the warfarin dose response variance was accounted for by a model involving age (20.9%), VKORC1-1639G/A (11.3%), and CYP2C9*1, *2, and *3 variants (7.1%). These results corroborate previous findings on warfarin pharmacogenetics and define a contrastable gene-bioenvironment interaction model suited to be used in Hispanic populations.

KW - Colombia

KW - CYP2C9

KW - Genetic isolate

KW - Pharmacogenetics

KW - VKORC1

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=76049103379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76049103379&partnerID=8YFLogxK

U2 - 10.1177/1076029608330472

DO - 10.1177/1076029608330472

M3 - Article

VL - 16

SP - 83

EP - 90

JO - Clinical and Applied Thrombosis/Hemostasis

JF - Clinical and Applied Thrombosis/Hemostasis

SN - 1076-0296

IS - 1

ER -